Antioxidant Clinical Trials in Mild Cognitive Impairment and Alzheimer’s disease – Challenges and Perspectives

E-ISSN： 1873-4286|20|18|3083-3092

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.18, 2014-06, pp. : 3083-3092

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 5, 2016-02 ,pp. : 520-528

Bentham Science Publishers

Access to resources Recommend Favorite

Recruitment and Retention Strategies for Clinical Trials in Alzheimers Disease

By Sabbagh M.N.

Pharmaceutical Development and Regulation, Vol. 1, Iss. 4, 2003-01 ,pp. : 269-276

Adis International

Access to resources Recommend Favorite

Ongoing trials in Alzheimer’s disease

By Sramek J.J. Cutler N.R.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 4, 2000-04 ,pp. : 899-915

Informa Healthcare

Access to resources Recommend Favorite

NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimer’s Disease

Current Pharmaceutical Design, Vol. 20, Iss. 32, 2014-10 ,pp. : 5169-5179

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of Statins on Cognitive Function in Patients with Alzheimer's Disease in Galantamine Clinical Trials

By Winblad Bengt

Drugs & Aging, Vol. 24, Iss. 1, 2007-01 ,pp. : 57-61

Adis International

Access to resources Recommend Favorite